-
-
-
-
-
-
-
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
KalVista Pharmaceuticals (KALV) Enters Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan
-
-
-
-
-
-
-
KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial
-
-
-
-
-
-
-
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
-
-
-
-
-
-
-
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
-
-
-
-
-
-
-
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
KalVista Pharmaceuticals (KALV) Presents New Sebetralstat Data
-
15,422 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

